Abstract: Rinse-off of the volumizing compositions, having an acidic pH, and in the form of a lotion, gel or cream are disclosed. The compositions include one or more linear hairstyling polymers which exhibit polar behavior in acidic pH, such as polyvinylpyrrolidone, together with a selected group of polycationic hairstyling polymers, such as polyquaternium-37. The compositions not only provide a strong hair volumizing effect, but that effect is durable, being retained after two or more shampooing operations of the hair. The compositions are used by applying an effective amount to wet hair, leaving the composition for at least about three minutes, and rinsing the composition out of the hair.
Abstract: Long term storage stable pemetrexed-containing liquid pharmaceutical compositions are disclosed. The compositions can include pemetrexed or pharmaceutically acceptable salts thereof; an antioxidant selected from lipoic acid, dihydrolipoic acid, methionine and mixtures thereof; a chelating agent selected from lactobionic acid, sodium citrate, tribasic and mixtures thereof; and a pharmaceutically acceptable fluid. The pH of the compositions is in a range of about 8 to about 9.5. The pemetrexed-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 227 nm, after at least about 18 months of storage at a temperature of from about 5° C. to about 25° C. Methods of preparing the formulation as well as methods of treatment of pemetrexed-susceptible diseases using the same are also disclosed.
Type:
Grant
Filed:
July 26, 2011
Date of Patent:
May 23, 2017
Assignee:
EAGLE PHARMACEUTICALS, INC.
Inventors:
Nagesh R. Palepu, Philip Christopher Buxton
Abstract: Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.
Abstract: A method for treatment of acne by applying to human skin a topical composition. The method involves contacting the human skin of area of an afflicted subject with an effective amount of the composition containing chromium and magnesium sulfate, for a period of time sufficient to reduce the redness and blemishes associated with acne. The topical composition is formulated into a pharmaceutically acceptable medium to properly regulate the keratin and sebum production of the skin cells, thereby inhibiting the appearance of acne therefore. The preferred use of the foregoing composition and method is in the treatment of acne.
Abstract: In one aspect, compositions are described herein. In some embodiments, a composition comprises a polymer or oligomer formed from one or more polycarboxylic acids, one or more alcohols, and one or more catechol-containing species. In another aspect, methods of making a composition are described herein. In some embodiments, a method of making a composition comprises providing a polycarboxylic acid; providing an alcohol; combining the polycarboxylic acid with the alcohol; adding a catechol-containing species to the combination of the polycarboxylic acid and the alcohol; and forming a polymer or oligomer from the polycarboxylic acid, the alcohol, and the catechol-containing species. In some embodiments, the catechol-containing species comprises an amine moiety, a carboxylic acid moiety, or a hydroxyl moiety that is not part of the catechol group.
Type:
Grant
Filed:
January 30, 2013
Date of Patent:
May 9, 2017
Assignee:
Board of Regents, The University of Texas System
Abstract: Inside-out gelation process to generate hydrogel microcapsules (aka microbeads). Methods of encapsulating biological material in the microbead 3-dimensional hydrogel matrix are described herein. The process generally comprises formation of a mixture of a hydrogel precursor compound, an optional biological material, and a divalent cation. The mixture is then combined with alginate, to generate an alginate shell around droplets of the mixture, followed by gelation of the hydrogel precursor core, and removal of the temporary alginate shell to yield self-sustaining microbeads.
Type:
Grant
Filed:
June 3, 2015
Date of Patent:
May 9, 2017
Assignee:
Likarda, LLC
Inventors:
Karthik Ramachandran, Stephen Michael Harrington
Abstract: A sustained release microsphere formulation with a high drug load may be formed by a continuous oil-in-water emulsion process by combining an organic dispersed phase with an aqueous continuous phase. The dispersed phase may include an encapsulating polymer, a primary solvent, such as dichloromethane, a pharmaceutically effective amount of an active agent having a solubility relative to the dispersed phase, and a co-solvent, such as benzyl alcohol, which is capable of increasing the solubility of the active agent relative to the dispersed phase. The continuous phase may include an aqueous solution of polyvinyl alcohol and water.
Abstract: A method for preparing ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages. The method comprises nanolipidic vehicles in which ethanol-containing substances are encapsulated, said ethanol-containing nanolipidic vehicles can be combined with food products, desserts or beverage ingredients including those that are subsequently frozen. The food product, dessert or beverage can remain in a frozen state during consumption by an individual. A composition comprising ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages.
Abstract: A composition of matter is used as an ingredient in cosmetics comprising at least 0.5% by weight and preferably 1-30% by weight of highly refined cellulose fiber in a cosmetic composition. Additionally present in the composition are other conventional cosmetic ingredients as known in the art. This composition may include at least colorants (dyes and pigments), lipophilic materials, aqueous materials (water and aqueous solutions), waxes, binding agents (polymers, thickening agents), emollients, emulsifiers, thickening agents, antioxidants, natural and synthetic oils and extracts, clays, ultraviolet radiation absorbers, and the like.
Type:
Grant
Filed:
June 30, 2009
Date of Patent:
April 25, 2017
Assignee:
FIBERSTAR, INC
Inventors:
Brock Lundberg, Olivia Richardson, Laura Valverde
Abstract: The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.
Abstract: Compositions for increasing the rate of metabolism of alcohol in a human and preventing the symptoms of a hangover comprising amino acids of one or both of L-arginine or L-citrulline; one or more of L-glutamine, L-glutamic acid, L-glutamine or theanine; and one or both of L-tyrosine or L-phenylalanine. The compositions may also contain other ingredients, such as B vitamins and plant extracts.
Abstract: Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium nitrate, together with certain viscosity-increasing agents, such as water-soluble forms of methylcellulose or carboxymethylcellulose.
Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
Type:
Grant
Filed:
May 7, 2015
Date of Patent:
April 11, 2017
Assignees:
AstraZeneca AB, AstraZeneca UK Limited
Inventors:
Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
Abstract: A disposable paper towel with an anti-microbial lotion and is provided with a chromatic transfer indicator which undergoes a delayed, visually perceptible color change at a predetermined time after the towel is wetted. An anti-microbial lotion on the towel increases water absorbency times (WAR) to further promote lotion transfer to the skin and increase lotion transfer effectiveness.
Type:
Grant
Filed:
October 24, 2014
Date of Patent:
March 28, 2017
Assignee:
Georgia-Pacific Consumer Products LP
Inventors:
Phuong Van Luu, Anthony O. Awofeso, Craig D. Yardley, Kang Chang Yeh, Bruce W. Janda
Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals.
Type:
Grant
Filed:
July 8, 2010
Date of Patent:
March 28, 2017
Inventors:
Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Adam R. Dorfman, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
Abstract: A suspension which is suitable for oral administration, comprising simvastatin, at least one suspending agent, and at least one preservative, wherein at least 90 wt % of the particles of simvastatin are less than 100 ?m in diameter. The present invention also includes uses of the suspension and methods of making the suspension.
Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
March 21, 2017
Assignee:
KEMPHARM, INC.
Inventors:
Travis Mickle, Sven Guenther, Sanjib Bera
Abstract: The present disclosure relates to polymeric siloxane coated zinc oxide powders having a mean particle size number distribution (D50) ranging from about 300 nm to about 600 nm and their use in sunscreen compositions. The relatively high surface area (in relation to particles of <100 nm) avoids agglomeration resulting in ease of formulation and high dispersal of the particles which tends toward less light scatter and hence better transparency in formulations. Furthermore, the combination of the particular particle size number distribution (D50) of zinc oxide ranging as above with bis(resorcinyl)triazine UV absorbers shows unexpected increased UV-A absorbance (320 to 400 nm) in comparison to the zinc oxide and bis resorcinyl triazine UV absorbers on their own at the same concentration.
Abstract: In some example embodiments, there is provided a method for sunless tanning. The method may include applying a sunless tanning solution to the skin and applying, during a drying stage of the sunless tanning solution, a powder to at least dry the tanning solution. Related compounds and methods may also be disclosed.
Abstract: Kits for biological control of leaf-cutting ants are disclosed. The kits comprise at least two granulated bait formulations, each formulation containing a) a biologic control agent for the ants, and b) one masking substance for the control agent and/or one attractant, wherein the control agent is the same in all formulations, and wherein the masking substance and/or attractant are different in each formulation.